| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Research Abstract |
To establish the molecular targeting therapy focused on an anti-aging gene, SIRT1 for human musculoskeletal malignancies, we assessed the expression of SIRT1 in various musculoskeletal tumors, and evaluated the effect of SIRT1 inhibition in human MFH cell lines. SIRT1 highly expressed in tissues from osteosarcomas and MFHs, compared to benign schwannomas, and the inhibition of SIRT1 decreased the cell viability in human MFH cells. Our findings strongly indicate that SIRT1 can be a novel therapeutic target for molecular targeting therapy on human musculoskeletal malignancies, and further studies on the roles of SIRT1 in musculoskeletal malignancies will be needed.
|
